NASDAQ · CADL
Healthcare · Biotechnology
$10.23
Down-$0.36 (-3.52%)
Updated Oct 6, 2026, 11:28 PM
SID Score
6.0/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance · CADL
1M range · 20 trading sessions · Daily adjusted prices
Prices through Oct 5, 2026
CADL closed at $10.23 after 20 trading sessions, down 18.81% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 5, 2026 | $10.27 | $10.45 | $9.94 | $10.23 | 980.89K |
| Oct 2, 2026 | $10.29 | $10.37 | $10.03 | $10.18 | 878.8K |
| Oct 1, 2026 | $10.72 | $10.72 | $10.16 | $10.16 | 1.04M |
| Sep 30, 2026 | $11.02 | $11.245 | $10.37 | $10.44 | 1.27M |
| Sep 29, 2026 | $11.25 | $11.25 | $10.57 | $10.88 | 963.29K |
| Sep 28, 2026 | $10.98 | $11.52 | $10.76 | $11.19 | 771.02K |
| Sep 25, 2026 | $11.50 | $11.55 | $11.01 | $11.02 | 799.76K |
| Sep 24, 2026 | $11.22 | $11.59 | $10.85 | $11.55 | 883.11K |
| Sep 23, 2026 | $11.93 | $12.0056 | $11.27 | $11.29 | 1.29M |
| Sep 22, 2026 | $11.28 | $11.96 | $11.15 | $11.85 | 882.04K |
| Sep 21, 2026 | $11.85 | $11.8999 | $11.13 | $11.21 | 1.09M |
| Sep 18, 2026 | $11.28 | $11.38 | $10.78 | $10.85 | 3.01M |
| Sep 17, 2026 | $10.95 | $11.50 | $10.86 | $11.34 | 798.62K |
| Sep 16, 2026 | $11.16 | $11.43 | $10.83 | $11.02 | 1.17M |
| Sep 15, 2026 | $10.63 | $11.14 | $10.41 | $11.12 | 1.07M |
| Sep 14, 2026 | $10.41 | $10.97 | $10.32 | $10.675 | 940.8K |
| Sep 11, 2026 | $11.32 | $11.41 | $9.855 | $10.545 | 3.6M |
| Sep 10, 2026 | $12.05 | $12.05 | $11.20 | $11.33 | 1.95M |
| Sep 9, 2026 | $12.52 | $12.78 | $12.13 | $12.17 | 661.25K |
| Sep 8, 2026 | $12.57 | $12.8458 | $12.02 | $12.60 | 1M |
The latest Smart Investors Daily articles mentioning CADL.
Company
Market Activity
Research & News
CADL research
Company profile and research snapshot.
Candel Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing viral immunotherapies to help patients fight cancer. The company has established two clinical-stage viral immunotherapy platforms based on novel, genetically modified adenovirus and herpes simplex virus (HSV) constructs, respectively.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Sep 21, 2026 | B of A Securities | Buy | — |
| Aug 14, 2026 | B of A Securities | Neutral | — |
| Aug 13, 2026 | HC Wainwright & Co. | Buy | — |
| Jul 13, 2026 | Stifel | Buy | — |
| Apr 20, 2026 | Cantor Fitzgerald | Overweight | — |
No generated briefing is available yet.
Yahoo · Sep 30, 2026
Candel’s experimental therapy combined with radiation therapy improved outcomes in patients with localized prostate cancer
Yahoo · Sep 30, 2026
Novel systemic immune data demonstrated T-cell activation following local administration of aglatimagene. Together with recently disclosed evidence of persistent local immune remodeling, these findings provide mechanistic support for the long-term clinical outcomes, including disease-free survival and prolonged time to biochemical failure, time to metastasis, and time to salvage anti-cancer therapy, observed in this patient populationBiodistribution and shedding data from the PrTK05 phase 2 tria
Yahoo · Sep 30, 2026
AI-enabled digital pathology analysis shows aglatimagene significantly increased lymphocyte infiltration and immune engagement with tumor cells compared to standard-of-care radiotherapy alone two years after treatment NEEDHAM, Mass., Sept. 30, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal immunotherapies to improve disease outcomes for patients with cancer, today announced the
Benzinga · Sep 30, 2026
Novel systemic immune data demonstrated T-cell activation following local administration of aglatimagene. Together with recently disclosed evidence of persistent local immune remodeling, these findings provide
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning CADL.
